NZ204708A

NZ204708A - Controlled release naproxen tablets

Info

Publication number: NZ204708A
Application number: NZ204708A
Authority: NZ
Inventors: C C H Hsiao
Original assignee: Syntex Pharma Int
Priority date: 1983-06-14
Filing date: 1983-06-27
Publication date: 1984-12-14
Also published as: NO842362L; NL191669C; FI842400A0; CA1204671A; AU1801183A; FI83037B; CH643455A5; NL191669B; FI83037C; NL8302842A; SE8304393L; ATA191084A; IE55585B1; DE3329265A1; ZA835591B; DK162814B; PH17827A; IE831799L; SG80990G; AU552080B2

Description

AMENDED under Section of tfee Patoots Act 1953 fronJ 11 • 3... •%£> ASSIST^C^COMMISSIONER OF PATENTS 2 047 0 8 . I f ■ (p 8 »j Monty , . r> ■"'r:r>n't"rsr> F ISO" CoropSeto u*. _ C* * i ' 5 J Ho: ISLbS JUNfy 48 W NEW ZEALAND Patents Act 1953 dlTljL N.Z.No.

COMPLETE SPECIFICATION "CONTROLLED RELEASE NAPROXEN AND NAPROXEN SODIUM TABLETS" We, SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED, of Corner House, Church Street, Hamilton, Bermuda; having a real and effective establishment at 23/25 Marlow Road, Maidenhead, Berkshire SL6 7AA England, incorporated under the laws of Bermuda, do hereby declare the invention, for which we pray that a Patent may be granted to u& and the method by which it is to be performed, to be particularly described in and by the following statement : - (followed by 1A) 204708 CONTROLLED RELEASE NAPROXEN AND NAPROXEN SODIUM TABLETS BACKGROUND OF THE INVENTION 1. Field of the Invention.

^ The present invention relates to controlled release preparations of (+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid (naproxen) and its pharmaceutically acceptable sodium salt (naproxen sodium). Specifically it relates to an oral dosage form 2q comprising a homogeneous dispersion of naproxen or naproxen sodium in a matrix of hydroxypropyl-methylcellulose, which provides a release period suitable for daily dosing and exhibits good bioavailability. 2. Description of Related Art. 2g Naproxen and naproxen sodium are well known and widely used anti-inflammatory medications with analgesic and antipyretic properties. They are used for the relief of pain and inflammation generally, and for specific conditions such as arthritis and dysmenorrhea. Naproxen 2Q is available in 250 mg, 375 mg and 500 mg tablets and is generally administered in therapeutic doses of 500-1000 mg per day with dosing intervals of 8-12 hours. Naproxen sodium is available in 275 mg tablets and is generally * 2047 administered in therapeutic doses of 550-1100 mg per day with dosing intervals of 8-12 hours.

Hydroxypropylmethylcelluloses are commercially available in various grades, under several tradenames, 5 including Methocel E,F,J and K (all previously designated as Methocel HG) from The Dow Chemical Co., U.S.A., HPM from British Celanese, Ltd., England, and Metolose SH from Shin-Etsu, Ltd., Japan. The various grades available under a given tradename represent differences 10 in methoxy and hydroxypropoxyl content as well as molecular weight and viscosity. Commercial designations of the various hydroxypropylmethylcelluloses reflect their individual viscosity types and are based on the viscosities of 2% aqueous solutions at 20° C as ■jg determined according to the method described in the United States Pharmacopeia, Rev. 20. The viscosities range from 15 cps to 30,000 cps and represent number average molecular weights of from about 10,000 to over 150,000. Each of the various grades under a given 20 tradename is a hydroxypropylmethylcellulose of a single viscosity type, e.g. 50 cps, 100 cps, 4000 cps, 15,000 cps, etc.

The area of controlled release pharmaceuticals is increasingly important in the formulation, manufacture 25 and marketing of new pharmaceutical products. The technologies and corresponding products of this art are variously described as, among others, sustained release, controlled release, prolonged action, depot, repository, delayed action, retarded release, and timed release 2Q pharmacueticals. In describing the present invention, the term "controlled release" is used to indicate that control is exercised over both the duration and profile of the in vivo drug release curve.

Controlled release drug dosage forms offer many 35 advantages over conventional dosage forms for particular 2047 03 drugs. Of major importance both practically and therapeutically is the decrease in frequency of administration required to achieve the desired effect. A dosage form which is taken only once-a-day greatly 0 improves patient compliance, and by extending the drug's activity through the night, permits the patient to sleep undisturbed until the morning. By enhancing the acceptability of a medication regime, patient compliance, and hence therapy, is improved. ■jq Another important therapeutic advantage of some controlled release drug dosage forms is a reduction in the fluctuation of plasma drug concentrations. The pharmacologic basis for minimizing fluctuations in plasma drug levels derives from three basic principals. First, every drug has a therapeutic blood level that must be reached if the desired benefit is to be achieved from its use. When the condition being treated requires multiple doses over an extended period of time, the therapeutic blood level is the drug level which must be maintained to / 2Q maximize the effectiveness of the medication. Second, most drugs have toxic blood levels that define the limit above which adverse reactions, or side effects, are experienced. Third, the drug concentration-response curve for most drugs is such that activity is approximately proportional to the logarithm of concentration. From these pharmacologic principles, a rationale for closely maintained plasma drug levels can be inferred. Several years of clinical testing has supported that rationale, and it is now widely agreed ^that where continuous drug treatment is desirable, therapy is optimized when the plasma drug concentration is maintained near the therapeutic level.

The mode of drug administration can influence the time course of therapeutic activity by affecting the „profile of drug concentration in the blood. Conventional 35 7 O Z1 C-. n J** Vv' ^ drug dosage forms are rapidly absorbed into the circulation and then metabolized; the blood level profile of the drug following a single conventional dose typically is defined by an initial high peak, followed by 5 a rapid decline, the slope and duration of which depends upon such factors as the half-life of the drug. The initial high peak typically substantially exceeds the therapeutic plasma concentration range, and represents a large portion of the drug contained in the dosage form. 10 After multiple periodic doses, a steady state mean plasma drug concentration is achieved, but the absolute level fluctuates in peaks and troughs above and below the mean level.

In contrast, controlled release drug dosage forms ^ can extend the duration of therapeutic drug levels in the blood, and minimize or even avoid the initial spike in blood level concentration which is typical of conventional dosage forms. Additionally, while controlled release oral dosage forms do not inherently reduce the 20 fluctuations in plasma drug concentrations, an opportunity to minimize these fluctuations arises from the fact that the rate of drug release is metered over a prolonged period of time.

A decrease in the fluctuation of plasma drug levels 2g is achieved by balancing the in vivo release rate against the pharmacokinetics of the drug, i.e. absorption, distribution, metabolism and exretion, so that plasma drug level variation is minimized. The time course of change of drug concentration in the blood is the net result of the rate of delivery into, and the pharmacokinetic behavior of the drug in, the body.

Conventional dosage forms of naproxen and naproxen sodium are administered two to three times daily in order to maintain therapeutic blood levels, and to minimize the 2gdifferential beteen peak and trough blood levels during 1 2 04', multiple dose therapeutic regimens. Peak to trough blood level ratios of about 2:1 are generally achieved with these regimens. In the interest of maximizing the therapeutic effectiveness of the drug, it is desirable to minimize as much as possible the ratio of peak to trough blood levels obtained during multiple dose therapy. Controlled release formulations generally permit less frequent dosing intervals to obtain acceptable peak to trough blood level ratios.

Many different types of controlled release oral dosage forms have been developed, but each has disadvantages which affect its suitability to a particular drug and therapeutic objective. Wide variations in the physicochemical and pharmacokinetic properties of different drugs impose such varied requirements on the design of controlled drug delivery formulations, that formulations which are suitable for one drug cannnot generally be predictably applied to other drugs. A formulation which incorporates the drug in a soluble or erodible matrix is desirable due to its ease of manufacture, low incidence of lot to lot variability, and relatively low cost. The use of hydrophilic gums such as hydroxypropylmethylcellulose as sustained release matrix materials is known and has been demonstrated with a variety of active agents. However, no formulation of this type is known which is well suited for the controlled release of either naproxen or naproxen sodium.

Christenson and Dale (U.S. Pat. No. 3,065,143) disclosed the use of certain hydrophilic gums, including hydroxypropylmethylcellulose, as carrier base materials in the preparation of sustained release pharmaceutical tablets. The tablets consisted essentially of a mixture of a drug in combination with at least one-third part by weight of the hydrophilic gum. Examples 1 and 7 disclose * 2 047 0 8 the use of Methocel 60HG 4,000 cps (now known as Methocel E4M) which has a number average molecular weight of 93,000, as calculated from the data in the "Handbook of Methocel Cellulose Ether Products" (The Dow Chemical Co., 5 1974). Example 4 discloses the use of Methocel 90HG 4,000 cps, and Example 5 discloses the use of Methocel 90HG 15,000 cps, (now known as Methocel E4M and K15M respectively). The 4,000 cps and 15,000 cps viscosity grades indicate that the polymers have number average 10 molecular weights of 89,000 and 124,000, respectively. Polymer to drug ratios given in the examples range from 1:2 to 10:1 and durations of sustained released of up to 12 hours in vitro are disclosed.

Schor and Nigalaye (U.S. Pat. No. 4,369,172, 1983) 12 have disclosed the use of certain hydroxypropylmethylcelluloses for "prolonged release therapeutic compositions." In that case, the carrier base is low viscosity hydroxypropylmethylcellulose having a number average molecular weight below 50,000 and a 20 hydroxy-propoxyl content of 9-12%. Specifically cited as examples corresponding to these criteria are Methocel E50 and Metolose 60SH50, which are 50 cps viscosity grade hydroxymethylcelluloses having number average molecular weights in the range of 23,000. Examples 1-4 describe 2g tablets consisting essentially of about 57% by weight of one or the other of these two materials in combination with lithium carbonate. The tablets weighed about 700 mg and released the active agent for up to 14 hours in vitro. Examples 5-6 describe sustained release aspirin 2Q tablets in which the hydroxypropylmethylcellulose carrier base constitutes 16.5% of the total weight of the tablet. The tablets had an average weight of 787 mg and released 650 mg aspirin in vitro over a period of 6-8 hours. Further examples in U.S. Pat. No. 4,369.172 show tablets ^containing 16-20% by weight of the polymer and release of 20470 the active ingredient over 1-6 hours in vitro.

The Dow Chemical Company publishes a brochure entitled "Formulating Sustained Release Pharmaceutical Products with Methocel" (1982) which describes the 5 various commercially available Methocel polymers, identifying their relative viscosities, rates of hydration and gel strength properties. The brochure also suggests criteria for formulating sustained release pharmaceutical products.

While the concept of utilizing hydroxypropyl methylcellulose in oral dosage forms to prolong the rate of release of drugs into the blood stream is known, and prolonged release of various active agents from such dosage forms has been demonstrated, the art available to 15 formulate oral controlled release forms of naproxen and naproxen sodium has several disadvantages. First, it is apparent from the foregoing discussion of the relevant art that presently known sustained release tablet formulations rely on fairly high levels of 20 hydroxypropylmethylcellulose to achieve adequate duration of drug release. The major problem with using any of these formulations is the additional bulk of the resulting tablet. In dry oral dosage forms, there is an approximate upper limit to the tablet bulk that will be 20 tolerated by the patient. This limit varies from patient to patient, but can be as low as 650 mg. Thus, with drugs such as naproxen, whose therapeutic dosage range is 500-1200 mg/day, the additional tablet bulk which is created by inclusion of substantial amounts of matrix ^material will render the tablets unacceptable to many patients.

Furthermore, while the art demonstrates in vitro sustained drug release from several formulations using hydroxypropylmethylcellulose, the pharmacokinetics of in 3^vivo drug release, absorption, distribution, metabolism 20470 and exretion impose more demanding requirements on the design of the controlled release tablet formulation than are apparent from in vitro testing. The present invention is directed to a new controlled release oral 5 dosage formulation for naproxen or naproxen sodium which provides sustained therapeutic plasma drug levels for at least 24 hours, and requires a surprisingly small amount, 4-9 weight percent, of hydroxypropylmethylcellulose. The low level of matrix material required by the present 10 invention makes possible a once-daily naproxen or naproxen sodium dosage form without excessive bulk, having weight and size characteristics which make it well-adapted for practical and acceptable patient administration. Chronic once-daily administration of the controlled release tablets of the present invention also provides less fluctuation in plasma drug concentration than is provided by chronic twice-daily administration of conventional naproxen and naproxen sodium tablets. Additionally, the new formulation is advantageous from a 20 a manufacturing viewpoint since it requires the presence of only three elements: the naproxen or naproxen sodium, the hydroxypropylmethylcellulose, and a lubricating agent.

SUMMARY OF THE INVENTION 25 The present invention is a controlled release tablet x for once-daily oral administration of 500-1200 mg of naproxen or naproxen sodium which is formed from a matrix comprising: about 4-9 weight percent of hydroxypropyl-20 methylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent of naproxen or naproxen sodium, 0.1 to about 2 weight percent of a pharmaceutically 25 acceptable lubricating agent, and 1 L U / U 0 to about 8 weight percent of other pharmaceutically acceptable excipients.

BRIEF DESCRIPTION OF DRAWINGS 5 FIGURE I is a graphical illustration of the results of the test described in Example 3 showing comparative plasma levels of naproxen over a 48 hour period achieved by single doses of two different 750 mg controlled release formulations prepared according to the present 1Q invention, as described in Examples 1 and 2 (lines A and B) as compared with a single dose (2x375 mg tablets) of Naprosyn* brand naproxen (line C).

FIGURE II is a graphical illustration of the results of the test described in Example 5 showing comparative ^ mean plasma concentrations of naproxen over a 24 hour period on day five of a multiple dose study. The mean plasma concentrations are steady state levels achieved by once-daily administration of the 750 mg controlled release formulation of the present invention (Formulation 20®, Example 2, line B of FIGURE,II), or by once every 12 hour administration of Naprosyn* brand naproxen, 375 mg (line C of FIGURE II).

DETAILED DESCRIPTION OF THE INVENTION 2g Accordingly, the present invention provides a new controlled release oral tablet for once daily administration of 500-1200 mg of naproxen or naproxen sodium which is formed from a homogeneous matrix comprising: about 4-9 weight percent of hydroxypropyl-methylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent of naproxen or naproxen sodium, 0,1 to about 2 weight percent of a pharmaceutically 1 2 0470 acceptable lubricating agent, and 0 to about 8 weight percent of other pharmaceutically acceptable excipients.

The tablet matrix includes a minor amount of a 5 pharmaceutically acceptable lubricating agent such as magnesium stearate to aid in the tableting process. This amount will vary between about 0.1 and 2% generally, and preferably represents about 1% of the total weight of the tablet. Suitable tablet lubricants include magnesium 10 stearate, stearic acid, calcium stearate and the like, or mixtures thereof. Magnesium stearate is preferred.

Optionally, the tablet matrix may include minor amounts of other pharmaceutically acceptable excipients such as colorants and glidents. Suitable colorants include, but are not limited to, FD& C Yellow #5, FD&C Yellow #6, and FD&C Blue #2, and generally represent 1% or less of the tablet weight. Suitable glidents include, but are not limited to, pharmaceutical grades of talc and fused silica, and generally represent 7% or less of the 2Q tablet weight.

The term matrix, as used herein, refers to a uniform mixture of naproxen, hydroxypropylmethylcellulose, a lubricating agent, and other optionally included excipients. An important aspect of the present invention __ is the fact that the hydroxypropylmethylcellulose is 25 uniformly dispersed throughout the matrix to achieve uniform drug release. The matrix may be made by any pharmaceutically acceptable technique which achieves uniform blending, including dry blending, conventional ^wet granulation, compression granulation, and fluid-bed granulation. Tablets can be made from the resulting matrix by any known tableting technique.

In accordance with the present invention, the amount of naproxen or naproxen sodium that is incorporated in a tablet may range between about 500 and about 1200 mg. *t,H' '■*-x /,' c",7 L / The therapeutic range of about 500-1100 mg per tablet is indicated for the treatment of pain of arthritis, dysmenorrhea and other conditions. The tablet of the present invention provides a release period suitable for g once-daily dosing, i.e. once within a 24 hour period. Generally, naproxen and naproxen sodium are administered at levels of 500-550, 750-800 or 1000-1100 mg/day, depending on the physician's judgement of the needs of the patient. Naproxen is generally administered at levels of 500, 750 or 1000 mg/day, while naproxen sodium is generally administered at levels of 550 or 1100 mg/day.

The hydroxypropylmethylcellulose utilized in the present invention is a water soluble cellulose ether, and is commercially available in various grades under the tradenames mentioned above in the BACKGROUND OF THE INVENTION. The physicochemical properties of these polymers vary over a wide range. Preferred embodiments ot this invention utilize premium grade polymers of a single viscosity type having number average molecular 2Q weights in the range of about 80,000-130,000.

The number average molecular weight of the hydroxypropylmethylcellulose which is used in the tablet matrix substantially influences the release profile which is obtained. The number average molecular weight (Mn) is the sum of the individual molecular weights of a representative sample population of molecules divided by the number of molecules in that sample, and is calculated from the limiting osmotic pressure of the solvent as the concentration of the hydroxypropylmethylcellulose approaches zero. The hydroxypropylmethylcellulose must have a number average molecular weight in the range of from about 80,000 to about 130,000, preferably from about 120,000 to about 130,000. When the polymer has a number average molecular weight of 120,000-130,000, it constitutes preferably about 4-6 weight percent of a * 2 a a J -'*> / u naproxen controlled release tablet, or about 6-8 weight percent of a naproxen sodium controlled release tablet. A second prefered range of number average molecular weight is about 85,000 to about 95,000. When the polymer 5 has a number average molecular within this range, it constitutes preferably about 7-9 weight percent of the controlled release naproxen or naproxen sodium tablet.

Hydroxypropylmethylcelluloses which have number average molecular weights in the range suitable for use 10 in the tablet matrix are available as single viscosity type polymers. As used herein, the term "single viscosity type" refers to commercially available grades of hydroxypropylmethylcellulose whose commercial designations reflect their individual viscosity type. 15 Examples of single viscosity type hydroxypropylmethylcelluloses which are suitable for use in the present invention include Methocel Premium K4M, A4M, E4M and F4M (Dow Chemical Co., U.S.A.) which are 4000 cps viscosity polymers having number average molecular 20 weights in the range of 85,000-95,000, and Methocel K15M, a 15,000 cps viscosity polymer having a number average molecular weight in the range of 120,000-130,000. Other suitable polymers include Metolose 60SH, 65SH, and 90SH, viscosity grades 4000, 8000, and 15,000 available 20 from Shin-Etsu Ltd., Japan. Specific preferred hydroxypropylmethylcelluloses are Methocel K4M Premium and Methocel K15M Premium.

The controlled release tablet of the present invention provides therapeutic blood levels of naproxen 20 or naproxen sodium for at least 24 hours, and is thus suitable for once-daily administration. Fluctuations in blood levels during multi-dose therapeutic regimens are minimized by the tablets of the present invention, such that the ratio of mean peak plasma concentration to mean 30 trough plasma concentration is 2:1 or lower.

The following examples serve to further illustrate the invention, but are not to be interpreted as limiting the scope of the appended claims in any way: EXAMPLES 1 and 2 1. Sustained Release Naproxen Tablets, 750 mg (Formulation A) Tablets were prepared from the following ingredients: Ingredients grams mg/tablet 1 naproxen, USP 3,555 750.0 2 hydroxypropylmethylcellulose, USP 356 75.1 15 2208, 15,OOOcps (METHOCEL K15M Premium) 3 magnesium stearate, NF 40 8.4 4 deionized water, USP 1,896ml * TOTAL WEIGHT 0.83 grams/tablet 2. Sustained Release Naproxen Tablets, 750 mg (Formulation B) Tablets were prepared from the following ingredients: Ingredients grams mg/tablet 1 naproxen, USP 3,402 750.0 2 hydroxypropylmethylcellulose, 179 39.5 2208, 15,000 cps (METHOCEL K15M Premium) 3 .magnesium stearate, NF 38 00 • 4 deionized water, USP 1.004 * TOTAL WEIGHT 0.8 0 grams/tablet * Removed during processing. 20470 Formulations A and B were prepared and made into tablets as follows: The naproxen and Methocel K15M were well blended, and then granulated with the purified water. The granulation was tray dried in a 50°C oven 5 for 16 hours, passed at slow speed through a hammer mill fitted with an 18 gauge screen, and then thoroughly mixed with the magnesium stearate. The resulting homogeneous matrix material was compressed into tablets of uniform weight and size. Tablets of Formulation A were 10 compressed at 3000 pounds load, and tablets of Formulation B were compressed at 4000 pounds load.

EXAMPLE 3 A study was performed to determine the blood levels 15 of naproxen after administration of single doses of controlled release Formulations A and B (Examples 1 and 2) over a 48 hour period using two Naprosyn* 375 mg tablets, a non-controlled release form of naproxen, as the reference standard. Six healthy male volunteers, 20 21-35 years of age were selected for the study. The participants were not permitted to use hypnotics, sedatives, antihistamines or other enzyme-inducing drugs for a month prior to, or during the study. No drugs, including all over-the-counter drugs, or alcohol, were 25 allowed 72 hours before or throughout the study period.

The study was performed as follows: Following an overnight fast, single dose of the study drug formulations were administered to each participant at 8:00 a.m. on each of three days of dosing 2Q which were one week apart. The participants were randomized, and each participant received each formulation once. The study participants continued to fast until the fourth hour blood sample had been obtained Ten milliliters of whole blood was collected in 35heparinized evacuated tubes on study days immediately 1 2(347 0 8 before dosing and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 36, and 48 hours post-dose. Plasma was separated and frozen for later assay of the naproxen plasma levels by HPLC. The resultant plasma levels 5 determined for Formulations A and B and the standard Naprosyn* tablet (Formulation C) are graphically depicted in Figure I.

EXAMPLE 4 0 Controlled Release Naproxen Sodium Tablets, 550 mg Tablets are prepared from the following ingredients: ^ Ingredients grams mg/tablet 1 naproxen sodium, USP 5,500 550.0 2 hydroxypropylmethylcellulose, USP 412.5 41.25 2208, 15,000 cps (Methocel K15M Premium) 3 talc, USP 315 31.5 20 4 magnesium stearate, NF 35 3.5 deionized water, USP n 2 ,100 36.0* TOTAL WEIGHT 662. 25 grams/tablet ♦remains as water of hydration for naproxen sodium 2g The naproxen sodium and Methocel K15M are well blended and then granulated with the purified deionized water. The granulation is tray dried in a 50°C oven for 12 hours, passed at slow speed through a hammer mill which is fitted with an 18 gauge screen, and then thoroughly mixed with the talc and magnesium stearate. The resulting homogeneous matrix material is then pressed into tablets of uniform size and weight with 3500 pounds load compression. * <: 0 4 7 EXAMPLE 5 A study was performed to determine the mean plasma levels of naproxen after multiple dosing of 750 mg controlled release naproxen tablets (Formulation B in 5 EXAMPLE 2) administered once every 24 hours, and of Naprosyn* brand naproxen (375 mg) tablets administered once every 12 hours. Twelve healthy male volunteers, 21-35 years of age were selected for the study. The participants were not permitted to use hypnotics, 10 sedatives, antihistamines, or other enzyme-inducing drugs for a month prior to, or during, the study. No drugs, including all over-the-counter drugs, or alcohol, were allowed 72 hours before, or during, the study period.

The study was designed as a two-way crossover in 15 which each subject received one of the study drugs over a five day period. Following an overnight fast, participants were administered one of the study drugs (either one 750 mg controlled release tablet of Formulation B, or one 375 mg Naprosyn* brand tablet), 20 at 9:00 a.m. according to a randomized schedule. At 9:00 p.m. those participants administered the reference prooduct, Naprosyn®, 375 mg, received their second dose of one Naprosyn* tablet. The participants were maintained on a daily dose of the same study drug 25 administered at the same time (or times) of the day for a total of 5 days.

Each day, immediately before the dose at 9:00 a.m., blood samples were drawn from each participant. Blood samples taken on the morning of the fifth day followed an 30 overnight fast. Subsequent blood samples were taken at 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours after the 9:00 a.m. dose on the fifth day. The samples were assayed for naproxen and the resulting mean plasma naproxen concentrations achieved by the controlled 35 release tablets (line B) and the non-controlled release aiaaao Naprosyn* tablets (line C) are shown in Figure II.

The results from this multiple dose study show that the naproxen biovailability achieved by once-daily administration of the controlled release tablet 5 (Formulation B) containing 750 mg of naproxen, is equivalent to that achieved by twice-daily administration of the Naprosyn* 375 mg tablets. The ratio of mean peak plasma level to mean trough plasma level achieved by once-daily administration of Formulation B tablets was 10 1.6:1, whereas the peak to trough plasma level ratio achieved by administration of Naprosyn* 375 mg tablets once every 12 hours was 1.9:1.

As used herein, the term "about", when used in reference to number average molecular weight, indicates that the actual number average molecular weight may vary up to 10% above or below the stated value.

As used herein, the term "about", when used with ref-20 erence to the amount of naproxen, naproxen sodium, lubricating agent or other optionally included pharmaceutically acceptable excipients, incorporated in each tablet, is intended to indicate that the actual amount of that ingredient may vary up to 10% above or below the stated amounts.

AS AMENDED o 7 r\ n ^ i 'J o

Claims

WHAT WE CLAIM IS:

1. A controlled release tablet for once-daily ^ oral administration of 500-1200,,nig of naproxen or , . . • i— 4ocmetA {yor^\ A, 5 naproxen sodium, said tablet being] a homogeneous matrix ^ comprising: 4-9 weight percent of hydroxypropylmethylcellulose having a number average molecular weight in the range of from 10 80,000 to 130,000, 81-96 weight percent of naproxen or naproxen sodium, 0 .1 to 2 weight percent of a pharmaceutically acceptable lubricating agent, and 0 to 8 weight percent of other pharmaceutically acceptable excipients.

2. The controlled release tablet of claim 1 which contains naproxen. 20

3. The controlled release tablet of claim 2 wherein the hydroxypropylmethylcellulose has a number average molecular weight of 120,000-130,000. 25

4. The controlled release tablet of claiYn 3 which comprises: 5 weight percent of the hydroxypropylmethylcellulose, 92-95 weight percent naproxen, 30 0,1 to 2 weight percent magnesium stearate, and 0 to 1 weight percent of a pharmaceutically acceptable colorant. 204703 -19-

5. The controlled release tablet of claim 4 , wherein the amount of naproxen is 500 mg.

6. The controlled release tablet of claim 5 which 5 contains 0.01-0.05 weight percent FD&C Yellow #6.

7. The controlled release tablet of claim 4 wherein the amount of naproxen is 750 mg. 10

8. The controlled release tablet of claim 7 which contains 0.01-0.05 mg FD&C Yellow #6.

9. The controlled release tablet of claim 4 wherein the amount of naproxen is 1000 mg. 15

10. The controlled release tablet of claim 9 which contains 0.01-0.05 mg FD&C Yellow #6.

11. The controlled release tablet of claim 1 2Q wherein the hydroxypropylmethylcellulose has a number average molecular weight of 120,000-130,000.

12. The controlled release tablet of claim 11 which comprises: 5 weight percent of the hydroxypropylmethylcellulose, 85-95 weight percent naproxen or naproxen sodium, 0.1 to 2 weight percent lubricating agent, and 0 to 8 weight percent other pharmaceutically acceptable excipients. 12 is 23940

13. The controlled release tablet of claim wherein the amount of naproxen or naproxen sodium 2g 500-550 mg. 4330J y v » f20M)6W&*J -20- 0470G

14. The controlled release tablet of claim 12 wherein the amount of naproxen or naproxen sodium is 750-800 mg. 5

15. The controlled release tablet of claim 12 wherein the amount of naproxen or naproxen sodium is 1000-1100 mg.

16. The controlled release tablet of claim 11 10 which comprises: 9 weight percent of the hydroxypropylmethylcellulose , 81-91 weight percent naproxen or naproxen sodium, ^ 0.1 to 2 weight percent lubricating agent, and 0 to 8 weight percent other pharmaceutically acceptable excipients.

17. The controlled release tablet of claim 16 2o wherein the amount of naproxen or naproxen sodium is 500-550 mg.

18. The controlled release tablet of claim 16 wherein the amount of naproxen or naproxen sodium is 25 750-800 mg.

19. The controlled release tablet of claim 16 wherein the amount of naproxen or naproxen sodium is 1000-1100 mg. 30

20. The controlled release tablet of claim 1 wherein the hydroxypropylmethylcellulose has a number average molecular weight of 85,000-95,000. 35 4330J k ? 23940 A >, i -21- 10

21. The controlled release tablet of claim 20 which comprises: 7-9 weight percent of the hydroxypropylmethylcellulose, 81-93 weight percent naproxen or naproxen sodium, 0.1 to . 2 weight percent lubricating agent, and 0 to 8 weight percent other pharmaceutically acceptable excipients.

22. The controlled release tablet of claim 21 wherein the amount of naproxen or naproxen sodium is 500-550 mg. 15

23. The controlled release tablet of claim 21 wherein the amount of naproxen or naproxen sodium is 750-800 mg.

24. The controlled release tablet of claim 21 20 wherein the amount of naproxen or naproxen sodium is 1000-1100 mg.

25. The controlled release tablet of claim 1 which contains naproxen sodium. 25

26. The controlled release tablet of claim 25 which comprises: 6-8 weight percent of hydroxypropylmethylcellulose having a number 20 average molecular weight in the range of 120,000-130,000, 82-90 weight percent naproxen sodium, 0.1 to 2 weight percent lubricating agent, 4-6 weight percent of a pharmaceutically acceptable glident, and 0 to 2 weight percent other pharmaceutically acceptable excipients. ■» _> 3

27. The controlled release tablet of cl^im 26 wherein the amount of naproxen sodium is . 550 mg.

28. The controlled release table of claim 26 5 wherein the amount of naproxen sodium is 1100 mg.

29. The controlled release tablet of claim 1 wherein the lubricating agent is magnesium stearate. ■jO

30. The controlled release tablet of claim 2 wherein the hydroxypropylmethylcellulose constitutes 4-6 weight percent of the tablet.

31. The controlled release tablet of claim 2 wherein the amount of naproxen is . 500 mg.

32. The controlled release tablet of claim 2 wherein the amount of naproxen is 750 mg. 20

33. The controlled release tablet of claim 2 wherein the amount of naproxen is 1000 mg. 25 30 SYNTEX PHARMACEUTICALS INTERNATIONA] LIMITED. By Their Attorneys HENRY HUGHES LIMITED By: